Intended for healthcare professionals

News

Seven days in medicine: 15-21 November 2017

BMJ 2017; 359 doi: https://doi.org/10.1136/bmj.j5382 (Published 23 November 2017) Cite this as: BMJ 2017;359:j5382

Regulation

Johnson & Johnson must pay $247m over faulty hip implants

The drug company Johnson & Johnson and its DePuy Orthopaedics unit were ordered to pay $247m (£186m; €210m) to six patients in New York who said that they were injured by defective Pinnacle hip implants. The case is the third in a row that the company has lost since winning a first test case in 2014. The defective implants were withdrawn from the market in 2013 when the Food and Drug Administration strengthened its regulations. This followed a BMJ investigation in 2012 that questioned the safety of metal-on-metal hips.1

No link is found between hormone test and birth defects

Campaigners called for a judicial review after a UK government report found that hormone based pregnancy tests (HPTs) given to women in the 1960s and ‘70s did not cause birth defects. An expert working group of the Commission on Human Medicines found no “causal association between the use of HPTs . . . and birth defects or miscarriage.” But Marie Lyon, chair of the Association for Children Damaged by Hormone Pregnancy Tests, said that the group would ask for a judicial review. (Full story doi:10.1136/bmj.j5352)

Funding

MPs call for cross party talks on NHS’s future

Ninety MPs from across the House of Commons urged the prime …

View Full Text

Log in

Log in through your institution

Subscribe

* For online subscription